Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJason R. WestinESElizabeth J. ShpallSNSattva S. Neelapu

Discussion

Loading...

Member takes

Overview

Retrospective review correlates CAR T cell kinetics with cytokine release syndrome and outcomes in mantle cell lymphoma, suggesting new interventions may improve therapy.

Key Points

  • To correlate CAR T cell kinetics and inflammatory markers with toxicities and outcomes after brexucabtagene autoleucel.
  • Retrospective review of 26 patients receiving brexucabtagene autoleucel.
  • Evaluation of CAR T cell expansion using flow cytometry-based assay.
  • Assessment of response and toxicities using specific criteria.
  • 88% of patients developed cytokine release syndrome, with 15% being grade 3+.
  • 73% achieved complete response at 30 days post-treatment.
  • Median progression-free survival was 13.5 months.

Cite This Study

Westin et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6a2https://doi.org/10.1182/blood-2025-7092
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial2025 · 5 citations
  2. 2Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 22026
  3. 3Clinical outcomes with brexucabtagene autoleucel in refractory mantle cell lymphoma: A systematic review and single-arm meta-analysis with contextual comparison to lisocabtagene maraleucel.2026
  4. 4Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy2025
  5. 5Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation2026